KEGG   DRUG: Cilgavimab
Entry
D11994                      Drug                                   
Name
Cilgavimab (USAN);
Cilgavimab (genetical recombination) (JAN)
Formula
C6626H10218N1750O2078S44
Exact mass
148959.5394
Mol weight
149051.3673
Sequence
(Heavy chain)
EVQLVESGGG LVKPGGSLRL SCAASGFTFR DVWMSWVRQA PGKGLEWVGR IKSKIDGGTT
DYAAPVKGRF TISRDDSKNT LYLQMNSLKT EDTAVYYCTT AGSYYYDTVG PGLPEGKFDY
WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG
VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKRVE PKSCDKTHTC
PPCPAPEFEG GPSVFLFPPK PKDTLYITRE PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN
AKTKPREEQY NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPASIEKTI SKAKGQPREP
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL
YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
(Light chain)
DIVMTQSPDS LAVSLGERAT INCKSSQSVL YSSNNKNYLA WYQQKPGQPP KLLMYWASTR
ESGVPDRFSG SGSGAEFTLT ISSLQAEDVA IYYCQQYYST LTFGGGTKVE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(Disulfide bridge: H22-H98, H158-H214, H234-L219, H240-H'240, H243-H'243, H275-H335, H381-H439, H'22-H'98, H'158-L'214, H'234-L'219, H'275-H'335, H'381-H'439, L23-L94, L139-L199, L'23-L'94, L'139-L'199)
  Type
Peptide
Class
Antiviral
 DG03174  Anti-SARS-CoV-2 agent
Remark
Product (mixture): D12262<US>
Efficacy
Antiviral
Comment
Monoclonal antibody
Treatment and prevention of SARS-CoV-2 infection
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko05171  Coronavirus disease - COVID-19
Brite
Drug groups [BR:br08330]
 Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D11994  Cilgavimab
Antimicrobials [BR:br08307]
 Antivirals
  Entry, fusion or uncoating inhibitor
   Coronavirus spike protein
    D11994  Cilgavimab (USAN)
Other DBs
CAS: 2420563-99-9

» Japanese version   » Back

DBGET integrated database retrieval system